Mount Vernon, Illinois Clinical Trials

A listing of Mount Vernon, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, …

monoclonal antibodies
neutrophil count
metastatic colorectal cancer
rifampin
oxaliplatin
Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 65 views
  • 22 Jul, 2021
  • +978 other locations
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery …

non-melanoma skin cancer
beta human chorionic gonadotropin
lobular carcinoma in situ
invasive carcinoma
human chorionic gonadotropin
Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 335 views
  • 21 Jul, 2021
  • +903 other locations
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with …

bilateral oophorectomy
dexamethasone
cyclophosphamide
nausea
vomiting
Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 109 views
  • 21 Jul, 2021
  • +595 other locations
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will …

Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 193 views
  • 10 May, 2021
  • +876 other locations
S0820 Adenoma and Second Primary Prevention Trial

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

anticoagulants
adenoma
aspirin
rectal carcinoma
unstable angina
Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 2518 views
  • 03 Mar, 2021
  • +1033 other locations
S1803 Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 …

daratumumab
induction therapy
aspirin
heparin
lenalidomide
Good Samaritan Regional Health Center
 (0.0 away) Contact site
  • 86 views
  • 07 Mar, 2021
  • +550 other locations
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted …

Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 0 views
  • 23 Jul, 2021
  • +762 other locations
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as avelumab, durvalumab, pembrolizumab, atezolizumab, and nivolumab, may help the body's immune …

Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +280 other locations
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical …

Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 0 views
  • 21 Jul, 2021
  • +260 other locations
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

This trial studies the effectiveness of two interventions on patient reported outcomes of patient centered communication and decision making about breast cancer treatment. The first intervention consists of enhancements to an existing patient-facing breast cancer treatment decision tool called iCanDecide that supports the management of worry, distress, and anxiety as …

Good Samaritan Regional Health Center
 (0.4 away) Contact site
  • 0 views
  • 23 Jul, 2021
  • +22 other locations